Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174004 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
A Phase 3 study of Parkinson's Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT01174004 is a Phase 3 study of Parkinson's Disease Psychosis that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 199 participants, below the 250-participant average among 3 other Parkinson's Disease Psychosis trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01174004, a Phase 3 study of Parkinson's Disease Psychosis, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Conditions Studied
Interventions
- DRUG placebo
- DRUG pimavanserin tartrate
Study Locations (20)
California
- - Carson
- - Fountain Valley
- - Fresno
- - Fullerton
- - Irvine
- - La Habra
- - La Jolla
- - Loma Linda
- - Oxnard
- - Pasadena
- - Reseda
- - Sunnyvale
- - Ventura
Arizona
- - Gilbert
- - Phoenix
- - Phoenix
- - Tucson
Florida
- - Boca Raton
- - Bradenton
Connecticut
- - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174004
The ClinicalTrials.gov registry entry for NCT01174004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 250-participant average among 3 other Parkinson's Disease Psychosis trials with a reported enrollment target (20% lower). The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease Psychosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01174004 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01174004 about?
NCT01174004 is a clinical study titled "A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis". The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
What is the current status of trial NCT01174004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 199 participants. The study started on 2010-07. Estimated completion is 2012-11.
What conditions does trial NCT01174004 study?
This clinical trial studies the following conditions: Parkinson's Disease Psychosis.
What interventions are being tested in trial NCT01174004?
The interventions under investigation include: placebo (DRUG), pimavanserin tartrate (DRUG).
Who is sponsoring clinical trial NCT01174004?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01174004 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.